1. Pink Sheet

Apogenix And EMA To Settle On Phase III Plans For PRIME Candidate Asunercept

 
• By Neena Brizmohun

Apogenix will ask the European Medicines Agency to consider a conditional approval strategy for its novel glioblastoma drug, asunercept, when it meets the regulators in early November.

Tumour
Apogenix and EU regulators are to discuss the next steps for the company's glioblastoma drug • Source: Shutterstock

Apogenix is gearing up for a meeting with the European Medicines Agency where the company will discuss the next crucial steps in the development of its glioblastoma drug, asunercept, which secured a place on the regulator’s hugely popular priority medicines scheme, PRIME, in May.

The discussions are due to take place on Nov. 6 under PRIME’s initial kick-off meeting for asunercept (APG101). The focus...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By Vibha Sharma

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 
• By Eliza Slawther

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.